SCHEMBL180124

SCHEMBL180124

Cc1[c]ccc(Cl)c1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1969747 0.79
SCHEMBL9243350 0.79
SCHEMBL2351350 0.75
SCHEMBL2344895 0.75
SCHEMBL5205859 0.75
SCHEMBL11562093 0.75
SCHEMBL11720223 0.74 NOTUM (0.35)
SCHEMBL60891 0.72
SCHEMBL11405867 0.72 PDK2 (0.34)
SCHEMBL7455214 0.72 POLB (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 140 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11712438-B2 Phenyl derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2023-08-01 US claimed
EP-3625222-B1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2021-07-21 EP claimed
US-20200179383-A1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2020-06-11 US claimed
EP-3625222-A1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2020-03-25 EP claimed
CN-110612296-A Phenyl derivatives as PGE2 receptor modulators 爱杜西亚药品有限公司 2019-12-24 CN claimed
US-10179790-B2 MTH1 inhibitors for treatment of cancer THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) 2019-01-15 US claimed
WO-2018210994-A1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2018-11-22 WO claimed
US-20170197976-A1 MTH1 INHIBITORS FOR TREATMENT OF CANCER THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) 2017-07-13 US claimed
EP-3152195-A1 MTH1 INHIBITORS FOR TREATMENT OF CANCER Thomas Helledays Stiftelse För Medicinsk Forskning (SE) 2017-04-12 EP claimed
WO-2015187088-A1 MTH1 INHIBITORS FOR TREATMENT OF CANCER THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) 2015-12-10 WO claimed
EP-1912941-B1 PIPERIDINE DERIVATIVES ASTRAZENECA AB (SE) 2012-11-14 EP claimed
US-20090197914-A1 Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them ASTRAZENECA AB (SE) 2009-08-06 US claimed
US-20090023733-A1 Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them ASTRAZENECA AB (SE) 2009-01-22 US claimed
EP-1994002-A1 PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AstraZeneca AB (SE) 2008-11-26 EP claimed
CN-101268049-A Novel piperidine derivatives ASTRAZENECA AB (SE) 2008-09-17 CN claimed
US-20080207688-A1 Novel Piperidine Derivatives ASTRAZENECA AB (SE) 2008-08-28 US claimed
EP-1912941-A1 NOVEL PIPERIDINE DERIVATIVES AstraZeneca AB (SE) 2008-04-23 EP claimed
WO-2007102767-A1 PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ASTRAZENECA AB (SE) 2007-09-13 WO claimed
WO-2007011293-A1 NOVEL PIPERIDINE DERIVATIVES ASTRAZENECA AB (SE) 2007-01-25 WO claimed
US-11712438-B2 Phenyl derivatives as PGE2 receptor modulators IDORSIA PHARMACEUTICALS LTD (CH) 2023-08-01 US disclosed
EP-3625222-B1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2021-07-21 EP disclosed
US-20200179383-A1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2020-06-11 US disclosed
EP-3625222-A1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2020-03-25 EP disclosed
CN-110612296-A Phenyl derivatives as PGE2 receptor modulators 爱杜西亚药品有限公司 2019-12-24 CN disclosed
US-10179790-B2 MTH1 inhibitors for treatment of cancer THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) 2019-01-15 US disclosed
WO-2018210994-A1 PHENYL DERIVATIVES AS PGE2 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2018-11-22 WO disclosed
CN-107709334-A New amino acid derivativges, its preparation method and include their Pharmaceutical composition 法国施维雅药厂 2018-02-16 CN disclosed
EP-3045450-B1 INTERMEDIATE COMPOUNDS IN PROCESSES FOR PRODUCING PYRIDAZINONE COMPOUNDS SUMITOMO CHEMICAL CO (JP) 2018-02-07 EP disclosed
US-20170197976-A1 MTH1 INHIBITORS FOR TREATMENT OF CANCER THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) 2017-07-13 US disclosed
EP-3152195-A1 MTH1 INHIBITORS FOR TREATMENT OF CANCER Thomas Helledays Stiftelse För Medicinsk Forskning (SE) 2017-04-12 EP disclosed
CN-104277004-B Prepare method and its intermediate of pyridazinone compound 住友化学株式会社 2016-08-24 CN disclosed
EP-3045450-A1 INTERMEDIATE COMPOUNDS IN A PROCESS FOR PRODUCING PYRIDAZINONE COMPOUNDS SUMITOMO CHEMICAL CO., LTD. (JP) 2016-07-20 EP disclosed
EP-2614053-B1 METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATES THEREOF SUMITOMO CHEMICAL CO (JP) 2016-03-23 EP disclosed
WO-2015187088-A1 MTH1 INHIBITORS FOR TREATMENT OF CANCER THOMAS HELLEDAYS STIFTELSE FÖR MEDICINSK FORSKNING (SE) 2015-12-10 WO disclosed
CN-105143206-A Pyrimidine-2,4-diamine derivatives for treatment of cancer THOMAS HELLEDAYS STIFTELSE F R MEDICINSK FORSKNING 2015-12-09 CN disclosed
US-9040709-B2 Method for producing pyridazinone compounds and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-05-26 US disclosed
US-20140378688-A1 METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL CO (JP) 2014-12-25 US disclosed
US-8884010-B2 Method for producing pyridazinone compounds and intermediate thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-11-11 US disclosed
US-20130172556-A1 METHOD FOR PRODUCING PYRIDAZINONE COMPOUNDS AND INTERMEDIATE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-07-04 US disclosed
WO-2013015394-A1 COMPOSITION AND METHOD FOR CONTROLLING HARMFUL ARTHROPODS SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2013-01-31 WO disclosed
US-20130023562-A1 NOVEL PIPERIDINE DERIVATIVES ASTRAZENECA AB (SE) 2013-01-24 US disclosed
EP-1620400-B1 piperidinylmethylpiperidine derivatives and their use as chemokine modulators ASTRAZENECA AB (SE) 2012-12-05 EP disclosed
US-8314127-B2 Piperidine derivatives ASTRAZENECA AB (SE) 2012-11-20 US disclosed
EP-1912941-B1 PIPERIDINE DERIVATIVES ASTRAZENECA AB (SE) 2012-11-14 EP disclosed
EP-2402316-A1 Piperidine derivatives AstraZeneca AB (Publ) (SE) 2012-01-04 EP disclosed
US-8008232-B2 Such as N-(3',4'-dichlorobiphenyl-2-yl)-5-chloro-1,3-dimethyl-1H-pyrazole-4-carboxamide; seeds BASF AKTIENGESELLSCHAFT (DE) 2011-08-30 US disclosed
US-7956070-B2 Piperidines as chemokine modulators (CCR) ASTRAZENECA AB (SE) 2011-06-07 US disclosed
US-20090197914-A1 Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them ASTRAZENECA AB (SE) 2009-08-06 US disclosed
US-20090118513-A1 Chemical Compounds ASTRAZENECA AB (SE) 2009-05-07 US disclosed
US-20090118288-A1 N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor ASTRAZENECA AB (SE) 2009-05-07 US disclosed
US-7517989-B2 Piperidine derivatives useful as modulators of chemokine receptor activity ASTRAZENECA AB (SE) 2009-04-14 US disclosed
US-20090069325-A1 Piperidine Derivatives Useful as Modulators of Chemokine Receptor Activity ASTRAZENECA AB (SE) 2009-03-12 US disclosed
US-7495013-B2 Chemical compounds ASTRAZENECA AB (SE) 2009-02-24 US disclosed
US-7482363-B2 Piperidine derivatives useful as modulators of chemokine receptor activity ASTRAZENECA AB (SE) 2009-01-27 US disclosed
US-20090023733-A1 Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20090012125-A1 Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them CAGE PETER 2009-01-08 US disclosed
EP-2010175-A1 PIPERIDINE DERIVATIVES USEFUL FOR TREATING OSTEOARTHRITIS AND OSTEOARTROSIS AstraZeneca AB (SE) 2009-01-07 EP disclosed
EP-1996551-A2 PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. AstraZeneca AB (SE) 2008-12-03 EP disclosed
EP-1994002-A1 PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AstraZeneca AB (SE) 2008-11-26 EP disclosed
EP-1994003-A1 PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM . AstraZeneca AB (SE) 2008-11-26 EP disclosed
US-20080275084-A1 Piperidines for the Treatment of Chemokine Mediated Diseases ASTRAZENECA AB (SE) 2008-11-06 US disclosed
US-20080262037-A1 Piperidine Derivatives for the Treatment of Chemokine Mediated Disease ASTRAZENECA AB (SE) 2008-10-23 US disclosed
CN-101268049-A Novel piperidine derivatives ASTRAZENECA AB (SE) 2008-09-17 CN disclosed
US-20080207688-A1 Novel Piperidine Derivatives ASTRAZENECA AB (SE) 2008-08-28 US disclosed
EP-1625114-B1 Piperidine derivatives for the the treatment of chemokine or H1 mediated diseases ASTRAZENECA AB (SE) 2008-08-27 EP disclosed
US-20080200505-A1 Piperidines for the Treatment of Chemokine Mediated Diseases ASTRAZENECA AB (SE) 2008-08-21 US disclosed
US-20080153707-A1 Pyrazolecarboxanilides, Process for Their Preparation and Compositions Comprising Them for Controlling Harmful Fungi BASF AKITENGESELLSCHAFT (DE) 2008-06-26 US disclosed
EP-1487817-B1 PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2008-06-04 EP disclosed
EP-1919884-A1 N-BENZYL-MORPHOLINE DERIVATIVES AS MODULATORS OF THE CHEMOKINE RECEPTOR AstraZeneca AB (SE) 2008-05-14 EP disclosed
US-20080108661-A1 Medicaments ASTRAZENECA AB 2008-05-08 US disclosed
EP-1912941-A1 NOVEL PIPERIDINE DERIVATIVES AstraZeneca AB (SE) 2008-04-23 EP disclosed
EP-1888527-A1 PIPERIDINES FOR THE TREATMENT OF CHEMOKINE MEDIATED DISEASES AstraZeneca AB (SE) 2008-02-20 EP disclosed
EP-1888526-A1 PIPERIDINES FOR THE TREATMENT OF CHEMOKINE MEDIATED DISEASES AstraZeneca AB (SE) 2008-02-20 EP disclosed
US-7307090-B2 Piperidine derivatives useful as modulators of chemokine receptor activity ASTRAZENECA AB (SE) 2007-12-11 US disclosed
WO-2007114770-A1 PIPERIDINE DERIVATIVES USEFUL FOR TREATING OSTEOARTHRITIS AND OSTEOARTROSIS ASTRAZENECA AB (SE) 2007-10-11 WO disclosed
WO-2007102769-A2 PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ASTRAZENECA AB (SE) 2007-09-13 WO disclosed
WO-2007102767-A1 PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM ASTRAZENECA AB (SE) 2007-09-13 WO disclosed
WO-2007102768-A1 PIPERIDINE DERIVATIVES, THEIR PROCESS FOR PREPARATION, THEIR USE AS THERAPEUTIC AGENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM . ASTRAZENECA AB (SE) 2007-09-13 WO disclosed
US-7265227-B2 Piperidine derivatives useful as modulators of chemokine receptor activity ASTRAZENECA AB (SE) 2007-09-04 US disclosed
EP-0980867-B1 KETONE DERIVATIVES AND MEDICINAL USE THEREOF TORAY INDUSTRIES (JP) 2007-08-08 EP disclosed
EP-1816123-A1 Intermediates for the production of pharmaceutically active compounds AstraZeneca AB (SE) 2007-08-08 EP disclosed
EP-1546130-B1 PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASE STATES ASTRAZENECA AB (SE) 2007-08-01 EP disclosed
CN-1938274-A Novel piperidines as chemokine modulators (CCR) ASTRAZENECA AB (SE) 2007-03-28 CN disclosed
US-20070054924-A1 Novel piperidines as chemokine modulators (ccr) ASTRAZENECA AB (SE) 2007-03-08 US disclosed
US-20070032523-A1 Chemical compounds ASTRAZENECA AB (SE) 2007-02-08 US disclosed
WO-2007011292-A1 N-BENZYL-MORPHOLINE DERIVATIVES AS MODULATORS OF THE CHEMOKINE RECEPTOR ASTRAZENECA AB (SE) 2007-01-25 WO disclosed
WO-2007011293-A1 NOVEL PIPERIDINE DERIVATIVES ASTRAZENECA AB (SE) 2007-01-25 WO disclosed
EP-1735298-A1 PIPERIDINE DERIVATES FOR THE TREATMENT OF CHEMOKINES MEDIARED DISEASE AstraZeneca AB (SE) 2006-12-27 EP disclosed
US-20060281726-A1 Piperidine derivatives for the treatment of chemokine or h1 mediated disease state ASTRAZENECA AB (SE) 2006-12-14 US disclosed
WO-2006126948-A1 PIPERIDINES FOR THE TREATMENT OF CHEMOKINE MEDIATED DISEASES ASTRAZENECA AB (SE) 2006-11-30 WO disclosed
WO-2006126947-A1 PIPERIDINES FOR THE TREATMENT OF CHEMOKINE MEDIATED DISEASES ASTRAZENECA AB (SE) 2006-11-30 WO disclosed
US-20060264463-A1 Chemical compounds MEDTECH CONVERGENCE FUND, L.P. 2006-11-23 US disclosed
EP-1713772-A1 NOVEL PIPERIDINES AS CHEMOKINE MODULATORS (CCR) AstraZeneca AB (SE) 2006-10-25 EP disclosed
EP-1363637-B1 PYRIMIDINE COMPOUNDS AND METHODS FOR THEIR PREPARATION UNIV HOLY GHOST DUQUESNE (US) 2006-08-09 EP disclosed
EP-1404667-B1 PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2006-03-08 EP disclosed
US-20060040984-A1 Novel piperidine derivatives for use in the treatment of chemokine medicated disease states ASTRAZENECA AB (SE) 2006-02-23 US disclosed
EP-1625114-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2006-02-15 EP disclosed
EP-1620400-A1 CHEMICAL COMPOUNDS AstraZeneca AB (SE) 2006-02-01 EP disclosed
EP-1611124-A1 PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CHEMOKINE OR H1 MEDIATED DISEASE STATE AstraZeneca AB (SE) 2006-01-04 EP disclosed
EP-1604982-A1 INTERMEDIATES FOR THE PREPARATION OF PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY AstraZeneca AB (SE) 2005-12-14 EP disclosed
WO-2005097775-A1 PIPERIDINE DERIVATES FOR THE TREATMENT OF CHEMOKINES MEDIARED DISEASE ASTRAZENECA AB (SE) 2005-10-20 WO disclosed
US-20050182094-A1 Piperidine derivatives useful as modulators of chemokine receptor activity ASTRAZENECA AB (SE) 2005-08-18 US disclosed
WO-2005073192-A1 NOVEL PIPERIDINES AS CHEMOKINE MODULATORS (CCR) ASTRAZENECA AB (SE) 2005-08-11 WO disclosed
US-20050176708-A1 Piperidine derivatives useful as modulators of chemokine receptor activity ASTRAZENECA AB (SE) 2005-08-11 US disclosed
EP-1546130-A1 NOVEL PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASE STATES AstraZeneca AB (SE) 2005-06-29 EP disclosed
EP-1487793-A1 PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY AstraZeneca AB (SE) 2004-12-22 EP disclosed
EP-1487817-A1 PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY AstraZeneca AB (SE) 2004-12-22 EP disclosed
US-20040235894-A1 Piperidine derivatives useful as modulators of chemokine receptor activity ASTRAZENECA AB (SE) 2004-11-25 US disclosed
WO-2004099144-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-11-18 WO disclosed
WO-2004087659-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2004-10-14 WO disclosed
WO-2004085423-A1 PIPERIDINE DERIVATIVES FOR THE TREATMENT OF CHEMOKINE OR H1 MEDIATED DISEASE STATE ASTRAZENECA AB (SE) 2004-10-07 WO disclosed
US-20040176411-A1 Piperidine derivatives useful as modulators of chemokine receptor activity ASTRAZENECA AB (SE) 2004-09-09 US disclosed
EP-1412330-A1 PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY AstraZeneca AB (SE) 2004-04-28 EP disclosed
WO-2004029041-A1 NOVEL PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASE STATES ASTRAZENECA AB (SE) 2004-04-08 WO disclosed
EP-1404667-A1 PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY AstraZeneca AB (SE) 2004-04-07 EP disclosed
WO-2003078421-A1 PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2003-09-25 WO disclosed
WO-2003078395-A1 PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2003-09-25 WO disclosed
US-6586369-B1 Agriculture BASF AKTIENGESELLSCHAFT (DE) 2003-07-01 US disclosed
WO-2003018556-A1 PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2003-03-06 WO disclosed
WO-2003004487-A1 PIPERIDINE DERIVATIVES USEFUL AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY ASTRAZENECA AB (SE) 2003-01-16 WO disclosed
US-6423720-B1 ANTICANCER AGENTS, ANTIBIOTIC DUQUESNE UNIVERSITY OF THE HOLY GHOST 2002-07-23 US disclosed
US-6184245-B1 Cyclic ketone derivatives and their medical applications TORAY INDUSTRIES INC. (JP) 2001-02-06 US disclosed
US-6100292-A Ketone derivatives and their medical applications TORAY INDUSTRIES, INC. (JP) 2000-08-08 US disclosed
EP-0980867-A1 KETONE DERIVATIVES AND MEDICINAL USE THEREOF TORAY INDUSTRIES, INC. (JP) 2000-02-23 EP disclosed
EP-0962456-A1 CYCLIC KETONE DERIVATIVE AND PHARMACEUTICAL USE THEREOF TORAY INDUSTRIES, INC. (JP) 1999-12-08 EP disclosed
US-5212179-A Antidepressants JOHN WYETH AND BROTHER LIMITED (GB) 1993-05-18 US disclosed
US-5196433-A 3-SUBSTITUTED PYRIDINEMETHANOLS AND FUNGICIDES CONTAINING THEM BASF AKTIENGESELLSCHAFT (DE) 1993-03-23 US disclosed
US-4985438-A PSYCHOTROPIC ACTIVITY, ANTIDEPRESSANTS JOHN WYETH & BROTHER, LIMITED (GB) 1991-01-15 US disclosed
EP-0193026-B1 SPECIAL EPOXY RESINS BAYER AG (DE) 1989-04-19 EP disclosed
US-4806552-A ANTIDEPRESSANTS JOHN WYETH & BROTHER, LIMITED (GB) 1989-02-21 US disclosed
US-4722930-A ANTIDEPRESSANTS JOHN WYETH AND BROTHER LIMITED (GB) 1988-02-02 US disclosed
EP-0227941-A1 1-Phenyl-4-(1H)-pyridazinimines, their preparation and use BASF Aktiengesellschaft (DE) 1987-07-08 EP disclosed
US-4563466-A ANTISEROTONINE JOHN WYETH & BROTHER LIMITED (GB) 1986-01-07 US disclosed
EP-0035374-B1 PIPERIDYL - UREA, - THIOUREA AND - GUANIDINE DERIVATIVES, AND INTERMEDIATES THEREFOR, PROCESSES FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE DERIVATIVES JOHN WYETH &amp; BROTHER LIMITED (GB) 1985-01-30 EP disclosed
US-4426387-A Piperid-4-yl ureas and thio ureas used as anti-depressant agents JOHN WYETH & BROTHER LTD. (GB) 1984-01-17 US disclosed
EP-0035374-A2 Piperidyl - urea, - thiourea and - guanidine derivatives, and intermediates therefor, processes for preparing them and pharmaceutical compositions containing the derivatives JOHN WYETH &amp; BROTHER LIMITED (GB) 1981-09-09 EP disclosed
US-4152329-A 2-ACYLAMINOTHIAZOL-4-YLACETAMIDES AS POST-EMERGENT SELECTIVE HERBICIDES GULF OIL CORPORATION (US) 1979-05-01 US disclosed
US-4120692-A Thio pyridine N-oxides and regulation of the natural growth and development of plants therewith UNIROYAL, INC. (US) 1978-10-17 US disclosed
US-4120690-A 2-Acylaminothiazol-4-ylacetamides as post-emergent selective herbicides GULF OIL CORPORATION (US) 1978-10-17 US disclosed
US-4050921-A Regulation of the natural growth or development of plants with 2-sulfinyl or 2-sulfonyl pyridine N-oxide compounds UNIROYAL INC. (US) 1977-09-27 US disclosed
US-4050921-A Regulation of the natural growth or development of plants with 2-sulfinyl or 2-sulfonyl pyridine N-oxide compounds UNIROYAL INC. (US) 1977-09-27 US disclosed